Actively Recruiting
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
Led by Cytrellis Biosystems, Inc. · Updated on 2025-12-31
10
Participants Needed
1
Research Sites
19 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity
CONDITIONS
Official Title
Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male and female adults between 30 and 65 years old
- Fitzpatrick Skin Type I through VI
- Moderate to severe wrinkles on the mid and lower face, scoring 3, 4, or 5 on the Lemperle Wrinkle Severity Scale
- Moderate to extreme abdominal laxity, scoring 2 to 4 on the Stokes Scale
- Willingness to sign the Informed Consent Form
You will not qualify if you...
- Pregnant women or nursing mothers
- Dermatosis, open wounds, sores, or irritated skin in the treatment area
- Allergy to stainless steel or medications used during the procedure such as petrolatum, lidocaine, bupivacaine, chlorhexidine, or povidone-iodine
- History or presence of any significant bleeding disorder
- Dermatological or autoimmune conditions affecting treatment outcomes, including but not limited to actinic keratosis, raised nevi, rosacea, melasma, active acne, papules/nodules, inflammatory lesions, dermatitis, psoriasis, cellulitis, urticarial folliculitis, scleroderma, rheumatoid arthritis, eczema, allergic dermatitis, collagen disorders, or lupus
- Systemic or acute local skin infections such as hepatitis A-F or HIV
- Use of high-dose anticoagulants or blood thinners within the past 14 days
- Recent chemotherapy, high-dose corticosteroids, or radiation in the treatment area
- Plastic surgery of the face within the past 12 months or facial scars less than 12 months old
- Injections of dermal fillers, fat, botulinum toxin, or other skin treatments in the treatment area within the past 6 months
- Scars in the treatment area less than 6 months old
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tri Valley Plastic Surgery
Dublin, California, United States, 94568
Actively Recruiting
Research Team
K
Karyn Siemasko, PhD
CONTACT
D
Delia Khayat, PharmD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here